Hutchison MediPharma

Company snapshot

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hutchison MediPharma. Not investment advice.

• What is Hutchison MediPharma?

  Hutchison Medipharma is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acute Myeloid Leukemia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and US

• Is Hutchison MediPharma publicly traded?

  Hutchison MediPharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Hutchison MediPharma develop or market?

  We link 1 drug profile(s) where Hutchison MediPharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dipharma-arzneimittel-gmbh#company-drugs.

• What are the latest developments for Hutchison MediPharma?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Hutchison MediPharma focus on?

  Hutchison MediPharma focuses on Acute Myeloid Leukemia based on our analysis of their pipeline programs and drug development activities.